WASHINGTON, DC – FEBRUARY 12: U.S. Sen. James Lankford (R-OK) speaks during a hearing of the Senate Homeland Security and Governmental Affairs Committee in the Dirksen Senate Office Building on February 12, 2026 in Washington, DC. The Department of Homeland Security has faced criticism over law enforcement tactics targeting undocumented immigrants and the killing of two U.S. citizens in Minneapolis. (Photo by Chip Somodevilla/Getty Images)

...

Suzanne Blake

By Suzanne Blake

Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


A new bipartisan Senate bill could lower prescription drug costs for tens of millions of Medicare beneficiaries by changing how Part D plans cover generic and biosimilar drugs.

The legislation, introduced by Senators James Lankford, a Republican from Oklahoma, and Maggie Hassan, a Democrat from New Hampshire, would require Medicare Part D plans to include lower‑cost generics when those alternatives are cheaper than brand‑name drugs.

“Right now, tiering games create backwards pricing. A generic insulin might cost $85 while the brand costs $40 because of how PBM [pharmacy benefit manager] rebates work. The bill stops that,” Michael Ryan, finance expert and founder of MichaelRyanMoney.com, told Newsweek. “Cheaper drugs go on lower tiers. No confusion. No choice between wallet and health.”

Read More on Politics

Why It Matters

Roughly 56 million people are enrolled in Medicare Part D. If passed, the bill would prevent these seniors from paying higher out‑of‑pocket costs due to pricing and formulary practices used by PBMs.

U.S. Senator James Lankford speaks during a hearing of the Senate Homeland Security and Governmental Affairs Committee on February 12 in Washington, D.C. (Photo by Chip Somodevilla/Getty Images)

...

What To Know

The newly introduced Ensuring Access to Lower‑Cost Medicines for Seniors Act would amend the Social Security Act to impose new requirements on Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage.

Under the bill, starting in plan years beginning on or after January 1, 2028, Part D formularies would be required to include generic drugs when they cost less than their brand‑name counterparts.

The list of drug options would also be required to include least one lower‑cost biosimilar when a reference biologic is covered and a cheaper biosimilar is available.

Lankford said the bill would eliminate pricing “gimmicks” that prevent savings from reaching patients.

"Most Oklahomans and Americans assume a generic drug will be cheaper at the pharmacy counter, but that's not always the case because of broken pricing practices. That's not right," Lankford said in a statement. "My bill makes sure lower-cost generics and biosimilars are actually cheaper than brand-name drugs at the pharmacy counter. It's a simple, commonsense fix to put patients first and end these pricing gimmicks."

In practical terms, the bill could reduce copays and coinsurance for beneficiaries whose plans currently place generics on higher‑cost tiers or exclude them altogether in favor of brand‑name drugs.

Part D beneficiaries often pay coinsurance, which is a percentage of a drug’s list price, rather than flat copays. In those cases, even small differences between brand‑name and generic prices can translate into meaningful out‑of‑pocket savings over a year.

If a brand‑name drug costs $400 per month and a generic alternative costs $80, a 25 percent coinsurance rate would mean $100 per month versus $20 per month. That’s a difference of roughly $960 per year for a single medication.

But actual savings would vary widely depending on drug mix and plan design.

“If Medicare Part D continues to prioritize covering lower cost generics, that should help put downward pressure on overall drug pricing over time,” Kevin Thompson, CEO of 9i Capital Group and host of the 9innings podcast, told Newsweek.

“Long term, anything that consistently reduces out of pocket healthcare costs for retirees is a net positive.”

Although the bill is bipartisan, support is limited. As of this week, it has two sponsors and no additional cosponsors and has been referred to the Senate Finance Committee.

“It's bipartisan and solves a specific problem voters care about,” Ryan said. “But standalone drug-pricing bills rarely move in Congress. Most likely path is attachment to a bigger must-pass bill.”

What Happens Next

The bill will remain in committee while senators weigh whether to expand support or attach it to broader Medicare or health care legislation.

If enacted, the changes would not take effect until 2028, giving the Centers for Medicare & Medicaid Services and insurers time to update formularies and cost‑sharing structures.

“The benefit is clear: it would result in cost savings for both seniors and the Medicare program,” Alex Beene, financial literacy instructor for the University of Tennessee at Martin, told Newsweek.

“Obviously, as with any program alteration, this bill passing isn't a guarantee, but it has already gained some bipartisan support and would look to positively affect a key group of Americans who will be voting in this year's mid-term.”

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines